# NAD Boosters and Human Function

NMN raises blood NAD; older-adult gait signals are tentative and inconsistent, with no established broader physical or longevity benefit.

Primary SC2 tentatively crosses Δ, with Low confidence, because the registered physical-function gate includes a genuine assigned secondary gait contrast. The quality concerns—multiple endpoints, incomplete twelve-week observations, an older trial allocation error and exploratory testing—are not hidden or converted into an unstated primary-endpoint requirement. Functional benefit is inconsistent across measures and contexts, and a separate emerging longer-dose trial adds a null boundary. Evidence does not establish broad strength/exercise efficacy, isolated NAD necessity or human longevity. SC1/SC3 marker-to-clinical inference and SC4 molecule equivalence remain separately bounded.

Several baseline disease, age, duration, dose and endpoint contexts were examined; results are heterogeneous and cross-trial contrasts do not prove treatment-by-subgroup interactions. The tentative positive is fixed to actual age65–75 twelve-week assigned gait, rather than redefining the entire claim to NAD responders. It does not yet provide sufficiently secure replicated context causality for Ε. Younger or shorter trials remain adjacent evidence, not failures or successes inside SC2.